TB Host Directed Therapy

Study Overview
=================
Brief Summary
-----------------
To examine the safety and preliminary efficacy of multiple adjunctive host directed TB therapies (TB HDT), to assess their potential to shorten TB treatment and/or prevent permanent lung damage.

Detailed Description
-----------------
OBJECTIVES: To determine the safety and preliminary efficacy of 4 TB HDT candidates: Safety (treatment emergent serious adverse events and SUSARs) Microbiologic effects in sputum (culture conversion, change in MGIT TTP) and blood (WBA) PET/CT imaging Serum markers of inflammation Effects on Mtb-specific and general immune function Pulmonary effects (spirometry, 6MWT, O2 saturation, and St. George Respiratory Symptom Questionnaire) In each case, TB HDT effects will be determined by comparison to patients treated with standard TB therapy alone with regard to a common set of primary and secondary endpoints. PRIMARY ENDPOINTS For auranofin, everolimus, and vitamin D: the proportions of patients experiencing suspected unexpected serious adverse reactions (SUSARs). For CC-11050: the proportion of patients experiencing treatment emergent serious adverse events (SAEs).

Official Title
-----------------
A Ph2 Randomized Trial to Evaluate the Safety Preliminary Efficacy and Biomarker Response of Host Directed Therapies Added to Rifabutin-modified Standard Therapy in Adults With Drug-Sensitive Smear-Positive Pulmonary TB

Conditions
-----------------
Tuberculosis

Intervention / Treatment
-----------------
* Drug: Everolimus 0.5 MG
* Drug: Auranofin 6 MG
* Drug: Vitamin D3
* Drug: CC-11050
* Drug: 2HRbZE/4HRb


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Willing and able to provide signed written consent or witnessed oral consent in the case of illiteracy, prior to undertaking any trial-related procedures. Aged 18 to 65 years, male, or if female, either not of reproductive potential (post-menopause, or status-post surgical sterilization) or with an intrauterine contraceptive device in place. Body weight (in light clothing without shoes) between 40 and 90 kg. First episode of pulmonary tuberculosis diagnosed by positive sputum AFB smear with subsequent culture confirmation OR positive Xpert TB/RIF with Ct <20 [4]. RIF susceptibility diagnosed by Xpert TB/RIF OR Hain test Chest radiograph meeting criteria for moderate or far advanced pulmonary tuberculosis [5] HIV-1 seronegative HBsAg negative Exclusion Criteria: Any condition for which participation in the trial, as judged by the investigator, could compromise the well-being of the subject or prevent, limit or confound protocol specified assessments Current or imminent treatment for malaria. Is critically ill, and in the judgment of the investigator has a diagnosis likely to result in death during the trial or the follow-up period. TB meningitis or other forms of severe tuberculosis with high risk of a poor outcome as judged by the investigator. History of allergy or hypersensitivity to any of the trial therapies or related substances, including known allergy or suspected hypersensitivity to rifampin or rifabutin. Having participated in other clinical trials with investigational agents within 8 weeks prior to trial start or currently enrolled in an investigational trial. Subjects with any of the following at screening: Cardiac arrhythmia requiring medication; Prolongation of QT/QTc interval with QTcF (Fridericia correction) >450 ms; History of additional risk factors for Torsade de Pointes, (e.g., heart failure, hypokalemia, family history of Long QT Syndrome); Any clinically significant ECG abnormality, in the opinion of the investigator. Patients requiring concomitant medications that prolong the QT inter-val. Random blood glucose >140 mg/dL, or history of unstable Diabetes Mellitus which required hospitalization for hyper- or hypoglycaemia within the past year prior to start of screening. Use of systemic corticosteroids within the past 28 days. Subjects with any of the following abnormal laboratory values: creatinine >2 mg/dL haemoglobin <8 g/dL platelets <100x109 cells/L serum potassium <3.5 aspartate aminotransferase (AST) ≥2.0 x ULN alkaline phosphatase (AP) >5.0 x ULN total bilirubin >1.5 mg/dL

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 2HRbEZ/4HRb<br>2HRbZE | Drug: 2HRbZE/4HRb<br> <br> * Other names: rifabutin-modified TB therapy;|
| Experimental: Everolimus<br>Everolimus 0.5 MG | Drug: Everolimus 0.5 MG<br> <br> Drug: 2HRbZE/4HRb<br> <br> * Other names: rifabutin-modified TB therapy;|
| Experimental: Auranofin<br>Auranofin 6 MG | Drug: Auranofin 6 MG<br> <br> Drug: 2HRbZE/4HRb<br> <br> * Other names: rifabutin-modified TB therapy;|
| Experimental: Vitamin D<br>Vitamin D3 | Drug: Vitamin D3<br> <br> Drug: 2HRbZE/4HRb<br> <br> * Other names: rifabutin-modified TB therapy;|
| Experimental: CC-11050<br>CC-11050 | Drug: CC-11050<br> <br> Drug: 2HRbZE/4HRb<br> <br> * Other names: rifabutin-modified TB therapy;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SAEs and SUSARs | For auranofin, everolimus, and vitamin D: the proportions of patients experiencing suspected unexpected serious adverse reactions (SUSARs). For CC-11050: the proportion of patients experiencing treatment emergent serious adverse events (SAEs). | through day 180 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| TEAEs other than SAEs and SUSARs | TEAEs other than SAEs, categorized according to severity, drug relatedness, and leading to early withdrawal. | through day 180 | 
| Sputum culture status on day 56 | Proportion of patients with positive sputum cultures on solid culture medium after 8 weeks of treatment | day 56 |